Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

europathy," noted Vahdat. "None of the reported cases of neuropathy were disabling, suggesting that eribulin mesylate, if approved, may be a useful addition to the treatment armamentarium for advanced breast cancer."

About Eribulin Mesylate

Eribulin mesylate is being developed by Eisai as a potential new chemotherapeutic agent. It suppresses the growth of microtubules, which are involved in various cellular processes in the body, such as cell division. Eribulin mesylate is a synthetic analog of halichondrin B, a naturally occurring compound which was first isolated from a marine sponge Halichondria okadai in 1992.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

(*) Censored observation.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Korea, Dec. 6 RNL Bio Co., ... specialized in adult stem cell therapeutics announced today ... Sclerosis improved tremendously after receiving stem cell treatment. ... autoimmune disease that affects the central nervous system ... is a disease in which the nerves of ...
(Date:12/4/2009)... inexpensive computer tool that measures volume changes in the ... by a CT scanner can rule out non-cancerous ones ... true cancers with fewer, less expensive and less invasive ... diagnostic guidelines are described in a paper published yesterday ...
(Date:12/4/2009)... Imaging (TDI), part of a Health & Wellness ... superior quality infrared imaging of the breast, neuromuscular ... assist in the early diagnosis of problems associated ... imaging cameras that "read" the entire infrared range ...
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Discover Health Through Awareness 2Discover Health Through Awareness 3Clearlycontacts Ca Named as One of Bc 26apos 3Bs Top Employers 59723 1Clearlycontacts Ca Named as One of Bc 26apos 3Bs Top Employers 59723 2Clearlycontacts Ca Named as One of Bc 26apos 3Bs Top Employers 59723 3Chiropractic Marketing Online Coach Launches First of a Kind Wealth Club for Chiropractors 59719 1Chiropractic Marketing Online Coach Launches First of a Kind Wealth Club for Chiropractors 59719 2Neiman Named Life Care 26apos 3Bs Vice President of Interior Design 59715 1Neiman Named Life Care 26apos 3Bs Vice President of Interior Design 59715 2
... Experience with Antimicrobials that are Biological Basis for ... Inc. (NYSE Amex: NBY ), a ... to treat and prevent a wide range of ... today announced an exclusive agreement with Professors Markus ...
... American Association for Cancer Research -PRINCETON, N.J., April ... ) today announced preclinical efficacy and safety data ... potentially important cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, ... antibody-drug conjugates. Data from the studies were presented ...
Other Medicine Technology:NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 2NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 3NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 4Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 2Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 3Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 4
(Date:12/6/2009)... -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Phase 2b 003-A1 study, known as the 003 ... pre-treated relapsed and refractory multiple myeloma patients. These ... Symposium at the 51st annual meeting of the ... Enrollment in this trial is complete (n=269), and ...
(Date:12/6/2009)... community, in cooperation with the Greater VA Healthcare System in West ... attendance is expected to soar to more than 5,000 veterans, active ... ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the ... Los Angeles, will once again create a holiday party. This year,s ...
(Date:12/5/2009)... The first Football,for Hope Centre in Khayelitsha ... doors,today (5 December 2009). FIFA President Joseph S. ... 2010 FIFA World Cup Organising Committee,South Africa (OC) ... Nematandani and Executive Mayor of the City of ...
(Date:12/5/2009)... Technology Center helps companies develop and test their cleaning processes. The ... variety of industries and solve problems for customers relating to cleaning ... ... 5, 2009 -- Midbrook, Inc , a Jackson, MI-based company, ...
(Date:12/4/2009)... Dec. 4 Care Investment Trust Inc. (NYSE: ... Board of Directors has declared a dividend of $0.17 per share ... 2009 to common shareholders of record on December 14, 2009. ... Investment Trust Inc. is a real estate investment and finance company ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... MESA, Calif., May 5 CNS Response, Inc.,(OTC ... appointed William E.,Bunney, Jr., MD to its Scientific ... Research and Distinguished Professor, Department of,Psychiatry and Human ... Len Brandt, Chairman and CEO of CNS Response, ...
... Doubles with More Than 175 Health Professionals From 13 ... Countries ... ), a global leader in the field of radiosurgery, today,announced that ... Massachusetts yielded record attendance with nearly double the,attendees over last year,s ...
... FARMINGTON, Conn., May 5 With advances ... physicians are now able,to effectively treat alcohol dependence ... has been a hit-or-miss proposition. When someone makes,the ... is important they,are connected with services as soon ...
... children with the developmental disorder, study finds , , MONDAY, ... autism have double the odds of having been hospitalized ... autism, according to a comprehensive review of Swedish medical ... for experts to start untangling the complex genetic and ...
... the U.S. to Address Epidemic Drug & Alcohol Use, by Suburban Teens; Integrates Academics, Intervention, Rehabilitation and ... Share Personal Stories, MENDHAM, N.J., May 5 , WHAT: ... week to dedicate ... nation,s only fully-licensed coeducational special ed ...
... Life-Changing Experiences, SAN RAMON, Calif., May 5 ... chain, today launched an innovative new advertising,campaign starring ... fitness. The "12 Million Lives" campaign is intended ... by using the power of fitness,to improve their ...
Other Medicine News:Health News:CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board 2Health News:CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board 3Health News:Robotic Radiosurgery Course Yields Record Attendance 2Health News:Robotic Radiosurgery Course Yields Record Attendance 3Health News:Robotic Radiosurgery Course Yields Record Attendance 4Health News:New Free Online Physician Locator for People Addicted to Alcohol 2Health News:Autistic Kids More Likely to Have Parents With Mental Illness 2Health News:Daytop - NJ to Dedicate New Preparatory School This Week 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 3
Black elastomer. Smooth finish. Non-Sterile....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Plastic Economical Single use. Non-Sterile....
Medicine Products: